SG10202010936RA - Glycotargeting therapeutics - Google Patents

JPS5742852A (en) 1980-08-27 1982-03-10 Seikagaku Kogyo Co Ltd Erythrocyte sensitized with antibody of polysaccharide of hemolytic streptococcus US5162512A (en) 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives CA1203164A (en) 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes EP0119650A3 (en) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics JPS59173762A (en) 1983-03-22 1984-10-01 Green Cross Corp:The Reagent for clotting reaction of red blood cell by reverse passive antibody CA1260827A (en) 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes WO1986001720A1 (en) 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates CA1330378C (en) 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs US5086002A (en) 1987-09-07 1992-02-04 Agen Biomedical, Ltd. Erythrocyte agglutination assay US20030022826A1 (en) 1987-09-08 2003-01-30 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens or infectious agents US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics KR100236375B1 (en) 1989-12-11 1999-12-15 오트리브 데이비스 더블유 Pharmaceutical compositions and kit for antibody targeting of diagnostic or therapeutic agents JPH0436185A (en) 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd Fused antigen polypeptide WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers KR950014915B1 (en) 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds EP0630407B1 (en) 1992-03-11 2000-08-02 PRENDERGAST, Kenneth, Francis Anti-viral fusion peptides GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use EP0716703A1 (en) 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin binding protein (gbp130) fusion compositions US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent PT743856E (en) 1994-02-28 2003-12-31 Univ Virginia ANTIGEN HETEROPOLYMES AND METHOD FOR THE TREATMENT OF AUTO-IMMUNE DISEASES USING THOSE HETEROPOLYMES US5698679A (en) 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin US5718915A (en) 1994-10-31 1998-02-17 Burstein Laboratories, Inc. Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof US20020187131A1 (en) 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom JPH10513350A (en) 1995-01-31 1998-12-22 ザ ロックフェラー ユニヴァーシティ Identification of DEC (dendritic and epithelial cells, 205 kDa), receptor with C-type lectin domain, nucleic acid encoding DEC, and uses thereof EP0837696B1 (en) 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents US6060054A (en) 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins AU4571097A (en) 1996-10-09 1998-05-05 Takeda Chemical Industries Ltd. A method for producing a microparticle US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors US20030103967A1 (en) 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors US20020081298A1 (en) 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors US20090280132A1 (en) 1997-01-07 2009-11-12 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease US20070218053A1 (en) 1997-01-07 2007-09-20 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes ES2289778T3 (en) 1997-04-18 2008-02-01 Biogen Idec Ma Inc. FUSION PROTEINS OF THE CONSTANT REGION OF THE IMMUNOGLOBULIN / RECEIVER TGF-BETA TYPE II. CU22737A1 (en) 1997-04-28 2002-02-28 Ct Ingenieria Genetica Biotech RECOMBINANT FUSION PROTEINS BASED ON BACTERIAL ADHESINS FOR THE DEVELOPMENT OF DIAGNOSTIC TESTS US6120770A (en) 1997-09-12 2000-09-19 University Of Notre Dame Du Lac Plasmodium proteins useful for preparing vaccine compositions US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use CA2318284A1 (en) 1998-01-15 1999-07-22 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand ATE262926T1 (en) 1998-01-29 2004-04-15 Poly Med Inc ASORBABLE MICROPARTICLES WO1999046392A1 (en) 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production EP1093378A4 (en) 1998-05-21 2001-10-10 Univ Pennsylvania COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING AN UNCONTROLLED FORMATION OF INTRAVASCULAR FIBRINE CLUBS. US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots CA2330939A1 (en) 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods AU5090899A (en) 1998-07-06 2000-01-24 University Of Tennessee Research Corporation, The Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors AU1103900A (en) 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction FR2794461B1 (en) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement PROCESS FOR THE PREPARATION OF NEW HUMAN IG FRACTIONS HAVING IMMUNOMODULATORY ACTIVITY AU7404800A (en) 1999-09-30 2001-04-30 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant US20030199043A1 (en) 2000-04-12 2003-10-23 Ballance David J. Albumin fusion proteins JP2004509978A (en) 2000-06-05 2004-04-02 ユニバーシティ　オブ　テネシー　コーポレイション Compositions and methods for endocytic presentation of immunosuppressive factors IL153853A0 (en) 2000-07-10 2003-07-31 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery WO2002011756A2 (en) 2000-08-07 2002-02-14 Entremed, Inc. Anti-plasmodium compositions and methods of use GB0019302D0 (en) 2000-08-08 2000-09-27 Univ Nottingham Trent Biological materials and the use thereof for the treatment of disease SE0003538D0 (en) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex US7132475B2 (en) 2000-10-19 2006-11-07 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems US7470420B2 (en) 2000-12-05 2008-12-30 The Regents Of The University Of California Optical determination of glucose utilizing boronic acid adducts US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10 EP1370588A2 (en) 2001-02-12 2003-12-17 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89) EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood CN1327927C (en) 2001-04-10 2007-07-25 生物功效学股份有限公司 Cell separation compositions and methods US7328453B2 (en) 2001-05-09 2008-02-05 Ecd Systems, Inc. Systems and methods for the prevention of unauthorized use and manipulation of digital content GB0113798D0 (en) 2001-06-06 2001-07-25 Chiron Spa Antigens and vectors for vaccination US20040185057A1 (en) 2001-06-15 2004-09-23 Kirkby Nikolai Soren Therapeutical vaccination CN100590131C (en) 2001-08-17 2010-02-17 埃克索泰拉有限公司 Methods and compounds for the targeting of protein to exosomes FR2829500B1 (en) 2001-09-13 2003-12-12 Hemosystem PROCESS FOR THE CONCENTRATION AND DETECTION OF PATHOGENIC SPROUTS FROM BLOOD PRODUCTS AND / OR DERIVATIVES THEREOF AND DEVICE FOR CARRYING OUT SAID METHOD KR20040058229A (en) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 Antibody targeting compounds EP1440090A2 (en) 2001-10-23 2004-07-28 Centre for Translational Research in Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide WO2003066820A2 (en) 2002-02-05 2003-08-14 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof JP4301567B2 (en) 2002-08-06 2009-07-22 ロマ リンダ ユニヴァーシティ Substances for preventing and treating autoimmune diseases US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments CA2505601C (en) 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators WO2004060910A2 (en) 2002-12-16 2004-07-22 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20 EP1605974B1 (en) 2003-03-04 2014-11-12 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells JPWO2004096859A1 (en) 2003-04-28 2006-07-13 積水化学工業株式会社 Chaperonin-target protein complex and production method thereof, target protein stabilization method, target protein immobilization method, target protein structure analysis method, sustained-release preparation, and antibody production method for target protein WO2004098645A1 (en) 2003-05-12 2004-11-18 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity US20050100964A1 (en) 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure WO2005051174A2 (en) 2003-11-21 2005-06-09 The Trustees Of Columbia University In The City Of New York Nucleic acid aptamer-based compositions and methods US20110064754A1 (en) 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines FR2869323B1 (en) 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne USE OF THE GENE ENCODING THE BETA CHAIN OF THE PROTEIN C4BP IN THE PRODUCTION OF RECOMBINANT DIMERIC PROTEINS NZ550600A (en) 2004-04-28 2010-03-26 Btg Int Ltd Epitopes related to coeliac disease WO2006002382A2 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates FR2873925B1 (en) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker WO2006034081A2 (en) 2004-09-17 2006-03-30 Massachusetts Institute Of Technology Polymers for analyte detection CN101151020B (en) 2005-02-07 2011-09-07 利波特卡有限公司 Adjuvanting material JP5214252B2 (en) 2005-03-03 2013-06-19 イミューノメディクス、インコーポレイテッド Humanized L243 antibody FR2884717B1 (en) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions ERYTHROCYTES CONTAINING ARGININE DEIMINASE WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs US7811809B2 (en) 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays RS53058B (en) 2005-07-08 2014-04-30 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof FI20050814A0 (en) 2005-08-11 2005-08-11 Procollagen Oy Procedure for observing autoantibodies formed in rheumatoid arthritis US20090130104A1 (en) 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation WO2007061936A2 (en) 2005-11-18 2007-05-31 New England Medical Center Hospitals, Inc. Clearance of abnormal iga1 in iga1 deposition diseases AU2006319216B2 (en) * 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens WO2007097934A2 (en) 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2 US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2 US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2 US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2 WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens CN101443351A (en) 2006-03-09 2009-05-27 阿普拉根有限公司 Modified molecules which promote hematopoiesis EP2007791A2 (en) 2006-03-09 2008-12-31 AplaGen GmbH Modified molecules which promote hematopoiesis US20090238883A1 (en) 2006-04-28 2009-09-24 Kren Betsy T Liver-specific nanocapsules and methods of using EP2041175A4 (en) 2006-06-23 2011-03-16 Augmenta Biolog Llc Targeted immune conjugates US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses CA2667637C (en) 2006-10-31 2021-04-20 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders JP2010509235A (en) 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ Treatment of multiple sclerosis WO2008057501A2 (en) 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells TWI422594B (en) 2007-02-02 2014-01-11 Baylor Res Inst Agent for presenting cells via a dendritic cell asialoglycoprotein receptor (DC-ASGPR) US7786267B2 (en) 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody NZ593450A (en) 2007-02-02 2012-08-31 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells TW200846363A (en) 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof EP3305805A1 (en) 2007-05-11 2018-04-11 Altor BioScience Corporation Fusion molecules and il-15 variants US8889140B2 (en) 2007-05-31 2014-11-18 Transtarget, Inc. Compositions and methods for tissue repair US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization GB2464887A (en) 2007-07-31 2010-05-05 Univ Johns Hopkins Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof WO2009051837A2 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis EP2219669A4 (en) 2007-12-19 2011-03-09 Mivac Dev Aktiebolag Compositions and methods for treatment of autoimmune and allergic diseases FR2925339B1 (en) 2007-12-24 2010-03-05 Erytech Pharma DRUG FOR THE TREATMENT OF PANCREATIC CANCER WO2009086552A1 (en) 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells ES2405258T3 (en) 2008-02-13 2013-05-30 Erytech Pharma Formulation and procedure for the prevention and treatment of skeletal manifestation of Gaucher disease FR2928270B1 (en) 2008-03-10 2011-01-21 Erytech Pharma FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES CA3044262C (en) 2008-03-28 2023-02-28 Mdna Life Sciences Inc. Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor CN102046661A (en) 2008-03-28 2011-05-04 加利福尼亚大学董事会 Polypeptide-polymer conjugates and methods of use thereof ES2542066T3 (en) 2008-04-29 2015-07-30 Immunexcite, Inc. Immunomodulatory compositions and methods of use thereof US8852640B2 (en) 2008-07-03 2014-10-07 Ecole Polytechnique Federale De Lausanne (Epfl) Micelles for delivery of nitric oxide EP2982695B1 (en) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprising antibodies to lingo or fragments thereof US8961991B2 (en) 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics CN101750244B (en) 2008-10-13 2014-03-12 艾博生物医药(杭州)有限公司 Method for separating red cells from blood sample and application WO2010045518A1 (en) 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof FR2938332B1 (en) 2008-11-07 2011-11-25 Erytech Pharma PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY US8268977B2 (en) 2008-11-20 2012-09-18 The Board Of Trustees Of The Leland Stanford Junior University Strongly quenching oligomeric excimer/quencher pairs for detection schemes US8835603B2 (en) 2008-11-30 2014-09-16 Immusant, Inc. Agents for the treatment of celiac disease FR2940087B1 (en) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement ERYTHROCYTES CONTAINING FACTOR VIII, PREPARATION AND USES. WO2010085509A1 (en) 2009-01-20 2010-07-29 Northwestern University Compositions and methods for induction of antigen-specific tolerance ES2622228T3 (en) 2009-03-10 2017-07-06 Baylor Research Institute Antiviral vaccines targeting antigen presenting cells CA3032548C (en) 2009-03-10 2023-05-09 Baylor Research Institute Anti-cd40 antibodies and uses thereof CA2755686A1 (en) 2009-03-16 2010-09-23 Daniel A. Vallera Methods and compositions for bi-specific targeting of cd19/cd22 FR2944106B1 (en) 2009-04-03 2012-09-28 Erytech Pharma METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP). PL2459220T3 (en) 2009-07-31 2021-03-08 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents US20110091493A1 (en) 2009-10-16 2011-04-21 Northwestern University Vaccine compositions and uses thereof DK2493487T3 (en) 2009-10-27 2016-12-05 Erytech Pharma Composition for induction of specific immunological tolerance WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates JP2013516967A (en) * 2010-01-14 2013-05-16 グラクソ グループ リミテッド Liver targeting domain antibody US9096655B2 (en) 2010-01-27 2015-08-04 Tata Memorial Centre Method for in-vivo binding of chromatin fragments US8592364B2 (en) 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy EP2544701B1 (en) 2010-03-08 2019-08-14 University of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof IT1399590B1 (en) 2010-04-26 2013-04-26 Erydel Spa APPARATUS AND KIT FOR ENCAPSING AT LEAST A COMPOUND FOR THERAPEUTIC AND / OR DIAGNOSTIC USE WITHIN ERYTHROCYTES DK2563753T6 (en) 2010-04-27 2016-04-04 Synaffix Bv Fused cyclooctynforbindelser and their use in metal-free click-reactions US20130115230A1 (en) 2010-04-30 2013-05-09 Augmenta Biologicals, Llc Delivery proteins WO2011154887A1 (en) * 2010-06-07 2011-12-15 Assistance Publique - Hopitaux De Paris Mellitin for the use thereof in the treatment of parkinson's disease US9326939B2 (en) 2010-07-31 2016-05-03 The Scripps Research Institute Liposome targeting compounds and related uses CA2807141C (en) 2010-07-31 2019-02-26 The Scripps Research Institute Compositions and methods for inducing immune tolerance US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics CN108129554A (en) 2010-08-10 2018-06-08 洛桑聚合联合学院 Erythrocyte binding therapeutic agent US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics JP6018069B2 (en) 2010-10-12 2016-11-02 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Methods and compositions for treating hemophilia B US20120121592A1 (en) 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells SE535625C2 (en) 2010-10-28 2012-10-16 Toleranzia Ab New compositions and procedures for the treatment of autoimmune and allergic diseases US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system WO2012112690A2 (en) 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom WO2013119857A1 (en) 2012-02-07 2013-08-15 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses ES2781773T3 (en) * 2012-02-15 2020-09-07 Ecole Polytechnique Fed Lausanne Epfl Erythrocyte binding therapeutics AU2013245645A1 (en) 2012-04-13 2014-11-13 Whitehead Institute For Biomedical Research Sortase- modified VHH domains and uses thereof WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis WO2014011465A2 (en) 2012-07-13 2014-01-16 Albert Einstein College Of Medicine Of Yeshiva University Aptamer-targeted antigen delivery US9771427B2 (en) * 2012-08-09 2017-09-26 Roche Glycart Ag ASGPR antibodies and uses thereof US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same CA2903021C (en) 2013-03-04 2022-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fusion proteins and immunoconjugates and uses thereof US10426794B2 (en) 2013-04-11 2019-10-01 The Brigham And Women's Hospital, Inc. Methods and compositions of treating autoimmune diseases US20160060324A1 (en) 2013-04-22 2016-03-03 James C. Paulson Methods and Compositions for Treating Bleeding Disorders US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics US10946079B2 (en) * 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation AU2015243380B2 (en) 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies CA2948165A1 (en) 2014-05-08 2015-11-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and compositions for treating autoimmune and inflammatory conditions WO2016022971A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins US20160060358A1 (en) 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES WO2016161372A1 (en) 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof CN107709356A (en) 2015-06-26 2018-02-16 南加利福尼亚大学 Masking Chimeric antigen receptor T cell for tumour-specific activation WO2017015141A1 (en) 2015-07-17 2017-01-26 President And Fellows Of Harvard College Humanized anti-glycophorin a antibodies and uses thereof WO2017023779A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies WO2017025889A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist EP4257126A3 (en) 2015-09-04 2023-12-06 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon CA2998115A1 (en) 2015-09-10 2017-03-16 Albert Einstein College Of Medicine, Inc. Synthetic antibodies to bax and uses thereof CN108430497B (en) 2015-09-19 2024-05-07 洛桑聚合联合学院 Sugar-targeted therapeutic agents JP2018531318A (en) 2015-09-29 2018-10-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Polymer conjugate vaccine CA3040110A1 (en) 2015-10-13 2017-04-20 Daniel C. Carter Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications CN108778308A (en) 2015-12-22 2018-11-09 库瑞瓦格股份公司 The method for producing RNA molecule composition JP7194593B2 (en) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド Covalent polymer antigen-conjugated particles KR20180105243A (en) 2016-02-09 2018-09-27 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. TIMPS encapsulating Japanese cedar pollen epitope WO2017139787A1 (en) 2016-02-12 2017-08-17 Bloodworks Therapeutic induction of tolerance using recombinant cell surface antigens US20170252417A1 (en) 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines CA3023092A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance SG11201809617RA (en) 2016-05-03 2018-11-29 Sqz Biotechnologies Co Intracellular delivery of biomolecules to induce tolerance US20170326213A1 (en) 2016-05-16 2017-11-16 Augusta University Research Institute, Inc. Protein-Coupled Red Blood Cell Compositions and Methods of Their Use JP6687498B2 (en) 2016-10-25 2020-04-22 住友ナコ フォ−クリフト株式会社 Mounting bracket for camera EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance WO2019098682A1 (en) 2017-11-14 2019-05-23 앱클론(주) Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same EP3774890A4 (en) 2018-03-26 2022-05-04 The University of Chicago METHODS AND COMPOSITIONS FOR TARGETING LIVER AND LYMPHATIC SINUSOIDAL ENDOTHELIAL CELL C-TYPE LECTIN (LSECTIN) WO2019215590A1 (en) 2018-05-07 2019-11-14 Anokion Sa Glycophorin a antigen-binding proteins CN112384239A (en) * 2018-05-09 2021-02-19 芝加哥大学 Compositions and methods for affecting immune tolerance EP4031173A1 (en) * 2019-09-20 2022-07-27 Anokion SA Compounds for the induction of antigen-specific immune tolerance